PE20140887A1 - Tratamiento de infecciones bacterianas - Google Patents

Tratamiento de infecciones bacterianas

Info

Publication number
PE20140887A1
PE20140887A1 PE2013001822A PE2013001822A PE20140887A1 PE 20140887 A1 PE20140887 A1 PE 20140887A1 PE 2013001822 A PE2013001822 A PE 2013001822A PE 2013001822 A PE2013001822 A PE 2013001822A PE 20140887 A1 PE20140887 A1 PE 20140887A1
Authority
PE
Peru
Prior art keywords
treatment
bacterial infections
refers
spp
mesalamine
Prior art date
Application number
PE2013001822A
Other languages
English (en)
Inventor
Yoshi Ichikawa
Sherwood Gorbach
Original Assignee
Optimer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46603355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140887(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Optimer Pharmaceuticals Inc filed Critical Optimer Pharmaceuticals Inc
Publication of PE20140887A1 publication Critical patent/PE20140887A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN COMPUESTO DE FORMULA (I); Y B) UN AGENTE ANTIINFLAMATORIO TAL COMO MESALAMINA, BUDESONIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UN METODO PARA TRATAR UNA INFECCION TAL COMO COLITIS CAUSADA POR LA BACTERIA CLOSTRIDIUM DIFFICILE, CLOSTRIDIUM PERFRINGENS, STAPHYLOCOCCUS SPP, ENTEROCOCCUS SPP, ENTRE OTROS, QUE COMPRENDE ADMINISTRAR UNA CANTIDAD DE 50MG A 1000MG DE LA COMPOSICION ENTRE UNO A TRES VECES POR DIA DURANTE UN PERIODO DE TRES A QUINCE DIAS
PE2013001822A 2011-02-04 2012-02-06 Tratamiento de infecciones bacterianas PE20140887A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161439673P 2011-02-04 2011-02-04
US201161552383P 2011-10-27 2011-10-27

Publications (1)

Publication Number Publication Date
PE20140887A1 true PE20140887A1 (es) 2014-08-14

Family

ID=46603355

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001822A PE20140887A1 (es) 2011-02-04 2012-02-06 Tratamiento de infecciones bacterianas

Country Status (10)

Country Link
US (1) US20140024609A1 (es)
EP (1) EP2670407A4 (es)
JP (1) JP2014504650A (es)
AU (1) AU2012211968A1 (es)
CA (1) CA2826662A1 (es)
CL (1) CL2013002235A1 (es)
CO (1) CO6811849A2 (es)
MX (1) MX2013009033A (es)
PE (1) PE20140887A1 (es)
WO (1) WO2012106722A2 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8903914D0 (sv) * 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
CA2596387C (en) * 2005-01-31 2012-11-20 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
US20080176927A1 (en) * 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins
TWI523654B (zh) * 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
PE20130310A1 (es) * 2010-05-18 2013-04-06 Optimer Pharmaceuticals Inc Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos

Also Published As

Publication number Publication date
MX2013009033A (es) 2013-09-06
CL2013002235A1 (es) 2014-01-03
EP2670407A4 (en) 2014-07-23
EP2670407A2 (en) 2013-12-11
WO2012106722A3 (en) 2013-01-10
CA2826662A1 (en) 2012-08-09
AU2012211968A1 (en) 2013-08-29
JP2014504650A (ja) 2014-02-24
US20140024609A1 (en) 2014-01-23
CO6811849A2 (es) 2013-12-16
WO2012106722A2 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
CO2017005870A2 (es) Compuestos de isoxazol de ácido hidroxámico como inhibidores de lpxc
NZ593111A (en) Antibacterial compounds
CL2011000939A1 (es) Compuestos derivados de cefalosporinas sustituidas por un grupo catecol, con actividad antimicrobiana contra bacterias gram negativo que producen betalactamasa; composicion farmaceutica que los comprende; uso en el tratamiento de enfermedades infecciosas.
PH12016501577A1 (en) Monobactam organic compounds for the treatment of bacterial infections
CL2013002185A1 (es) Compuestos derivados de terpenos modificados en c-17 y c3, inhibidores de la maduración del vih; compuestos intermediarios; composición farmacéutica que los comprende; su uso para tratar la infección por vih.
MX2013011526A (es) Derivados de isoxazol utiles como agentes antibacteriales .
MX2011009847A (es) Agentes antihelminticos y su uso.
CL2014000491A1 (es) Anticuerpos monoclonales neutralizantes de las exotoxinas tcda y/o tcdb de clostridium difficile; composición farmacéutica que los comprende; y uso para tratar infección por c. difficile.
PH12017500533A1 (en) 1-alkyl-6-oxo-1, 6-dihydropyridin-3-yl compounds and use as sgrm modulators
MX2011008043A (es) Derivados de actagardina.
MX2019013291A (es) Compuestos y metodos para tratar infecciones bacterianas.
MX2018001022A (es) Antibiotico aminoglucosido novedoso efectivo contra bacterias resistentes a multiples farmacos.
WO2012177075A3 (ko) 항생제 및 라이소포스파티딜콜린을 포함하는 면역 증강 또는 세균성 감염 질환 치료용 조성물
CL2013000331A1 (es) Compuestos derivados de triazina-1,2 diazol condezada o de triazina-1,2,4-triazol condensada; proceso para preparar estos compuestos; composicion farmaceutica; proceso para preparar esta composicion farmaceutica; y su uso para el tratamiento de una infeccion bacteriana tal como una infeccion por la bacteria clostridium.
MX377004B (es) Derivados de 2,3-dihidro-tiazolo[3,2-a]piridin-5-ona, intermediarios de los mismos, y su uso como agentes antibacterianos.
PE20140887A1 (es) Tratamiento de infecciones bacterianas
MX2016001912A (es) Metodos para tratar infecciones oticas luego de la colocacion de un tubo de timpanostomia.
BR112017008101A2 (pt) composto, composição farmacêutica, métodos para inibir o dnae bacteriano e para tratar uma infecção, e, uso de um composto.
JO3477B1 (ar) مركبات أحادي باكتام عضوية لعلاج العدوى البكتيرية
PH22015000375Y1 (en) Process of producing an ointment for treating skin infection caused by staphylococcus aureus bacteria
PH22015000376U1 (en) An ointment for treating skin infection caused by staphylococcus aureus bacteria

Legal Events

Date Code Title Description
FA Abandonment or withdrawal